Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada.
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):177-83. doi: 10.1016/j.cytogfr.2010.02.012. Epub 2010 Mar 12.
The use of viruses as targeted cancer therapy has shown significant promise, and the list of oncolytic viruses continue to grow. The interest in unexplored viruses as oncolytic agents is a natural corollary to the successes and challenges of those already being examined in the clinical setting. Are these 'new' viruses any more effective than their predecessors? What are the benefits of refining current clinical candidates compared to searching for new ones? This review briefly describes some of these novel oncolytic viruses. It also examines the issues that arise in comparing them to each other. We believe that the viral mechanism of action is a key factor to success and suggest guidelines by which all oncolytic virus candidates could be evaluated.
病毒作为靶向癌症治疗的应用已经显示出巨大的潜力，并且越来越多的溶瘤病毒被不断发现。对于那些尚未在临床环境中进行研究的病毒作为溶瘤剂的兴趣，是对已经在临床环境中进行研究的病毒的成功和挑战的自然推论。这些“新”病毒是否比它们的前身更有效？与寻找新病毒相比，改进当前的临床候选药物有什么好处？这篇综述简要描述了其中的一些新型溶瘤病毒。它还研究了将它们相互比较时出现的问题。我们认为病毒的作用机制是成功的关键因素，并提出了可以评估所有溶瘤病毒候选物的指导方针。
